Contact
searchSearch
HMP Global

Drug Recalls News

News
Repository Corticotropin Injection Recalled Due to the Presence of Particulate Matter
09/03/2026
Rebecca Amrick
Acthar Gel (repository corticotropin) injection is under a voluntary Class II recall due to the presence of particulate matter, affecting 12 367 vials.
Acthar Gel (repository corticotropin) injection is under a voluntary Class II recall due to the presence of particulate matter, affecting 12 367 vials.
Acthar Gel (repository...
09/03/2026
Pharmacy Learning Network
News
Clobetasol Propionate Cream Recalled Due to Failed Content Uniformity Specifications
09/03/2026
Rebecca Amrick
A voluntary Class II recall has been issued for clobetasol propionate cream after the product failed to meet content uniformity specifications.
A voluntary Class II recall has been issued for clobetasol propionate cream after the product failed to meet content uniformity specifications.
A voluntary Class II recall has...
09/03/2026
Pharmacy Learning Network
News
Tyenne Injection Recalled Due to the Presence of Particulate Matter
09/03/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for Tyenne (tocilizumab-aazg) injection after the firm discovered glass particles in the product, affecting 4643 vials.
The US Food and Drug Administration (FDA) has issued a Class I recall for Tyenne (tocilizumab-aazg) injection after the firm discovered glass particles in the product, affecting 4643 vials.
The US Food and Drug...
09/03/2026
Pharmacy Learning Network
News
Cemiplimab Injection Recalled Due to Lack of Sterility Assurance
08/27/2026
Rebecca Amrick
Libtayo (cemiplimab-rwlc) injection is under a voluntary Class II recall due to a lack of assurance of the product’s sterility, affecting 21 353 vials.
Libtayo (cemiplimab-rwlc) injection is under a voluntary Class II recall due to a lack of assurance of the product’s sterility, affecting 21 353 vials.
Libtayo (cemiplimab-rwlc)...
08/27/2026
Pharmacy Learning Network
News
Acamprosate Calcium Tablets Recalled Due to Failed Dissolution Specifications
08/27/2026
Rebecca Amrick
A voluntary Class II recall has been issued for acamprosate calcium tablets due to the product’s failure to meet dissolution specifications.
A voluntary Class II recall has been issued for acamprosate calcium tablets due to the product’s failure to meet dissolution specifications.
A voluntary Class II recall has...
08/27/2026
Pharmacy Learning Network
News
Morphine Injection Recalled Due to Labeling Mix-Up
08/27/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for morphine sulfate injection due to a mistake in product labeling, affecting 625 500 syringes.
The US Food and Drug Administration (FDA) has issued a Class I recall for morphine sulfate injection due to a mistake in product labeling, affecting 625 500 syringes.
The US Food and Drug...
08/27/2026
Pharmacy Learning Network
News
Valsartan Tablets Recalled Due to Failed Dissolution Specifications
08/20/2026
Rebecca Amrick
Diovan (valsartan) tablets are under a voluntary Class II recall after failing to meet dissolution specifications.
Diovan (valsartan) tablets are under a voluntary Class II recall after failing to meet dissolution specifications.
Diovan (valsartan) tablets are...
08/20/2026
Pharmacy Learning Network
News
Clindamycin Palmitate Hydrochloride Recalled Due to the Presence of Foreign Substance
08/20/2026
Rebecca Amrick
A voluntary Class II recall has been issued for clindamycin palmitate hydrochloride oral solution due to the presence of foreign particles in the product.
A voluntary Class II recall has been issued for clindamycin palmitate hydrochloride oral solution due to the presence of foreign particles in the product.
A voluntary Class II recall has...
08/20/2026
Pharmacy Learning Network
News
Kian Pee Wan Capsules Recalled Due to Undeclared Drug Ingredients
08/20/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for Kian Pee Wan capsules due to the presence of undeclared drug ingredients (dexamethasone and cyproheptadine), affecting 71 bottles.
The US Food and Drug Administration (FDA) has issued a Class I recall for Kian Pee Wan capsules due to the presence of undeclared drug ingredients (dexamethasone and cyproheptadine), affecting 71 bottles.
The US Food and Drug...
08/20/2026
Pharmacy Learning Network
News
Mirabegron Tablets Recalled Due to CGMP Deviations
08/13/2026
Rebecca Amrick
Mirabegron extended-release tablets are under a voluntary Class II recall after an N-nitroso mirabegron impurity was found in the product, violating Current Good Manufacturing Practice specifications.
Mirabegron extended-release tablets are under a voluntary Class II recall after an N-nitroso mirabegron impurity was found in the product, violating Current Good Manufacturing Practice specifications.
Mirabegron extended-release...
08/13/2026
Pharmacy Learning Network

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use